Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced its financial results for the year ended December 31, 2025, highlighting significant advancements in its pivotal Phase 3 clinical trial for IMNN-001, an innovative immunotherapy for advanced ovarian cancer. The company reported a net loss of $14.5 million, or $6.83 per share, a decrease from the previous year's loss of $18.6 million. Operating expenses were reduced by 23% to $14.7 million, primarily due to lower costs associated with clinical studies. Research and development expenses decreased by 33% to $7.8 million, reflecting the completion of the OVATION 2 Study and the initiation of the OVATION 3 Study. The company emphasized the promising results from the Phase 2 OVATION 2 Study, which demonstrated a median overall survival benefit of 14.7 months for patients treated with IMNN-001 compared to standard chemotherapy. The ongoing Phase 3 trial is expected to further validate the efficacy of IMNN-001, with enrollment ahead of schedule. Imunon plans to hold a conference call to discuss these results and provide a business update, showcasing its commitment to advancing treatment options for ovarian cancer patients.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.